YM155 (Sepantronium Bromide)

For research use only. Not for use in humans.

目录号:S1130

YM155 (Sepantronium Bromide) Chemical Structure

CAS No. 781661-94-7

YM155 (Sepantronium Bromide)是一种有效的survivin抑制药,通过抑制Survivin启动子活性而发挥作用,在HeLa-SURP-luc 和 CHO-SV40-luc细胞中IC50为0.54 nM;对SV40启动子活性抑制作用不显著,能够轻微抑制Survivin与XIAP相互作用。YM155 在乳腺癌细胞中可下调 survivinXIAP、调节自噬并诱导自噬依赖的DNA损伤。Phase 2。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 918.45 现货
RMB 568.29 现货
RMB 983.81 现货
RMB 2214.29 现货
RMB 6310.26 现货
RMB 10401.3 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的YM155 (Sepantronium Bromide)发表文献126篇:

产品安全说明书

Survivin抑制剂选择性比较

生物活性

产品描述 YM155 (Sepantronium Bromide)是一种有效的survivin抑制药,通过抑制Survivin启动子活性而发挥作用,在HeLa-SURP-luc 和 CHO-SV40-luc细胞中IC50为0.54 nM;对SV40启动子活性抑制作用不显著,能够轻微抑制Survivin与XIAP相互作用。YM155 在乳腺癌细胞中可下调 survivinXIAP、调节自噬并诱导自噬依赖的DNA损伤。Phase 2。
靶点
Survivin [1]
(HeLa-SURP-luc, CHO-SV40-luc cells)
0.54 nM
体外研究

YM155 30 μM时对SV40作用效果也不大。在p53缺陷的PC-3和PPC-1 人类HRPC细胞中,通过抑制 survivin基因启动子的转录,YM155显著抑制内源性survivin的表达。相反,YM155 100 nM时对c-IAP2, XIAP, Bcl-2, Bcl-xL, Bad, α-actin,及β-tubulin的蛋白表达仍没抑制效果。YM155作用于人类癌细胞系包括PC-3和PPC-1,使细胞发生凋亡,伴随着caspase-3活性上升。YM155有效抑制人类癌细胞系(突变p53或短小p53) 包括PC-3, PPC-1, DU145, TSU-Pr1, 22Rv1, SK-MEL-5及A375 ,IC50值为2.3到11 nM。[1]另外,YM155增强NSCLC细胞对γ-射线的敏感性。YM155和γ-射线联用,增强凋亡细胞数和caspase-3活性。 YM155推迟修复放射诱导核DNA断裂的双链。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kasumi-1 NVzBT2pCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfUfmc4OiCq M2jPSGROW09? MkHQTWM2OD1yLkCwPUDDuSByLkCwNFkh|ryP MYSyOVY2QTd|MR?=
M-07e MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHS2Rmo4OiCq NHPhWGlFVVOR MlzoTWM2OD1yLkC0NEDDuSByLkCxN{DPxE1? M3T6SlI2PjV7N{Ox
THP-1 NEXNeoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjIelc4OiCq MULEUXNQ NFr2fYJKSzVyPUCuNFUyKMLzIECuNFE{KM7:TR?= M1PGT|I2PjV7N{Ox
CMK MlnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nvTlczKGh? NHXFbZhFVVOR M362bGlEPTB;MD6wOVMhyrFiMD6wNFkh|ryP M4\WelI2PjV7N{Ox
MV4-11 M{\BZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV23NkBp NYXG[Iw1TE2VTx?= NV7W[pdlUUN3ME2wMlA2PSEEsTCwMlAzQCEQvF2= NVrmVmJJOjV4NUm3N|E>
AML-193 NEH0V4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3z3dVczKGh? M4fUWWROW09? MkjKTWM2OD1yLkS2NkDDuSByLkC2NEDPxE1? NVnBWnhwOjV4NUm3N|E>
HL-60 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlj1O|IhcA>? MWrEUXNQ NUXSRVc4UUN3ME2wMlAxOSEEsTCwMlAxODJizszN NXz2UZRZOjV4NUm3N|E>
ML-2 NHfrV|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rYTVczKGh? MULEUXNQ NET3elRKSzVyPUCuNFA6KMLzIECuNFAzKM7:TR?= NHXBOY0zPTZ3OUezNS=>
OCI/AML3 M2e4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37yfVczKGh? MUDEUXNQ M1OxSGlEPTB;MD6wNVEhyrFiMD6wNFIh|ryP NX7tdoxqOjV4NUm3N|E>
HEL NXjIUVYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUK3NkBp MXfEUXNQ NH21cVRKSzVyPUCuOVU6KMLzIECuNFM5KM7:TR?= MonVNlU3PTl5M{G=
ME-1 NF7NeG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DXNVczKGh? NFTRfJNFVVOR MlrUTWM2OD1yLk[4OEDDuSByLkG3PUDPxE1? MnywNlU3PTl5M{G=
THP-1 MUfBdI9xfG:|aYOgRZN{[Xl? M1rwdFHDqM7:TR?= MoHPO|IhcA>? NWnaeFhUTE2VTx?= M4DGR4lv\HWlZYOgZZBweHSxc3nz MmLNNlU3PTl5M{G=
M-07e MmHRSpVv[3Srb36gRZN{[Xl? M2rRdFDjiJNzwrFOwG0> MXG3NkBp MV\EUXNQ NVvKbHJvcW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBUfXK4aY\pci=> MkOxNlU3PTl5M{G=
THP-1 MYnGeY5kfGmxbjDBd5NigQ>? NX:5VpJYOOLCk{JCpO69VQ>? MXS3NkBp NF3mN45FVVOR NUjs[4JocW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBUfXK4aY\pci=> MVGyOVY2QTd|MR?=
CMK MljNSpVv[3Srb36gRZN{[Xl? MonGNQKBmzIEoN88US=> MmXzO|IhcA>? NGPSUXJFVVOR NWnNVpo3cW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBUfXK4aY\pci=> MmPvNlU3PTl5M{G=
AML-193 MYXGeY5kfGmxbjDBd5NigQ>? NHv5SnYx6oDVMdMg{txO M3;3R|czKGh? M{nH[WROW09? MkSzbY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDTeZJ3cX[rbh?= MYiyOVY2QTd|MR?=
Kasumi-1 NVLkfJl4TnWwY4Tpc44hSXO|YYm= Mo\PNQKBmzIEoN88US=> NGTuRW44OiCq MWnEUXNQ NYrUPW9ycW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBUfXK4aY\pci=> M2m4e|I2PjV7N{Ox
MV4-11 NYm0VG54TnWwY4Tpc44hSXO|YYm= MViw5qCUOcLizszN MlfZO|IhcA>? M4SzcGROW09? MlXYbY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDTeZJ3cX[rbh?= NGfIPJUzPTZ3OUezNS=>
MUG-Chor  MlKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWGwMVUh|ryP NFLaRVczPC92ODDo M{nWVGlEPTB;Nz6wOgKBkW6PIH\vdkA1QGh? NHrud3gzPTZ2MEG4OS=>
U-CH1  MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jBZlAuPSEQvF2= M2OyNlI1NzR6IHi= NH7pUGVKSzVyPUmuNFPjiImwTTDmc5IhPDiq NYPDcnJ4OjV4NECxPFU>
KATOIII MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXKxNE8zOCCwTR?= NX23OYU6PDhiaB?= NFflW5dqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M3nJUVI2PjN3MEW1
AGS  M3n2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHY[5NLOTBxMkCgcm0> NYC0S29sPDhiaB?= MmHkbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MmnSNlU3OzVyNUW=
SACC-83 MY\GeY5kfGmxbjDBd5NigQ>? MkDnOUBvVQ>? MnXDOFghcA>? NWDMSnRN\GWlcnXhd4V{KG63Y3zlZZIh\XiycnXzd4lwdiCxZjDITWYuOc7z MU[yOVQ5PTZ|NR?=
INA-6 NVfUeIFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnrNE02ODBibl2= M1zrSFQ5KGh? NFjrdWhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NFHNUGczPTJ7Nkm3PC=>
U-266 NXew[3NjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXZNE02ODBibl2= NXnF[pZCPDhiaB?= NHjlcmFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M2LG[lI2Ojl4OUe4
MOLP-8 M1nTbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rqeFAuPTByIH7N MX:0PEBp M4TySYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NYHJW2dYOjV{OU[5O|g>
HG-1 NHXURpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY[wMVUxOCCwTR?= MkXwOFghcA>? Mn\NbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M{\ES|I2Ojl4OUe4
NCI-H929 MmHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWSwMVUxOCCwTR?= NVy4PVA6PDhiaB?= NFnZUXVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MlXONlUzQTZ7N{i=
OPM-2 MmXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;VNE02ODBibl2= NEDNRYI1QCCq MXHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NInnNZkzPTJ7Nkm3PC=>
L-363 MnXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7tU|QxNTVyMDDuUS=> M2DRZ|Q5KGh? Mn63bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NYixXllHOjV{OU[5O|g>
MOLP-2 Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\1flAuPTByIH7N Mn\JOFghcA>? MYPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NGmwcXUzPTJ7Nkm3PC=>
KMS-12-BM MnvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1v4RlAuPTByIH7N MXy0PEBp NFLOcWxqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MUKyOVI6Pjl5OB?=
SK-MM-2 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnwNE02ODBibl2= M4HSZ|Q5KGh? M2K2b4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MnezNlUzQTZ7N{i=
U-266 MWnBdI9xfG:|aYOgRZN{[Xl? NEXaWmkxNTVyIH7N NXzDeYlMOjRiaB?= Mmm4bY5lfWOnczDhdI9xfG:|aYO= MoDMNlUzQTZ7N{i=
INA-6  NUDnSFVESXCxcITvd4l{KEG|c3H5 M2rldFAuPTBibl2= NEjW[4UzPCCq MnjSbY5lfWOnczDhdI9xfG:|aYO= NHS3Z4QzPTJ7Nkm3PC=>
MCF7 MlPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXm3NkBp NXnzZnhMUUN3ME2xN{DDuSB4IH7N M1LoZlI2OjJyMkK1
MCF7-TamR6 M2Tsfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDnW3g4OiCq MWrJR|UxRThiwsGgOkBvVQ>? NIi1U|MzPTJ{MEKyOS=>
MCF7-TamR7 NHTXcVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrVWoQ4OiCq MmnJTWM2OD16INMxJFMhdk1? M3Lx[FI2OjJyMkK1
MCF7-TamR8 M1nQeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUCyOFNRPzJiaB?= MknRTWM2OD1zNTFCtUA3KG6P NXey[VhiOjV{MkCyNlU>
MCF7-TamC3 NI[2VW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVG3NkBp NVHhN|F5UUN3ME22JOKyKDNibl2= MoW5NlUzOjB{MkW=
MCF7-TamC6 MoHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\ob5A{PzJiaB?= NVewWIwxUUN3ME22JOKyKDBwMTDuUS=> NXztbJBUOjV{MkCyNlU>
MDA-MB-231 NVuyWIV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHtNmFnPzJiaB?= MknLTWM2OD13INMxJFEhdk1? MWKyOVIzODJ{NR?=
SK-BR-3 NUXnbYNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXS3NkBp MmDyTWM2OD15INMxJFAvOyCwTR?= MX2yOVIzODJ{NR?=
Eca109 NX\YemF4TnWwY4Tpc44hSXO|YYm= M2DBTVEuPTBibl2= MVS0PEBp MknwSG1UVw>? NXu2RlZHe3WycILld5NmeyC|dYL2bZZqdiCneIDy[ZN{cW:wIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MViyOVE{QTN7NR?=
TE13 MnfSSpVv[3Srb36gRZN{[Xl? MVWxMVUxKG6P M{j5bFQ5KGh? MoLRSG1UVw>? NVPJ[FFxe3WycILld5NmeyC|dYL2bZZqdiCneIDy[ZN{cW:wIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MUKyOVE{QTN7NR?=
Eca109 MmLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fLU|AuOTByIH7N MlS1NlQwPDhiaB?= MkXqSG1UVw>? NUfUZ2Vm\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MWOyOVE{QTN7NR?=
TE13 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LudFAuOTByIH7N MUiyOE81QCCq MVjEUXNQ MV3k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mlr3NlUyOzl|OUW=
MT-3 NWfUSVNlU2mwYYPlJGF{e2G7 MXq3NkBp NUTO[FlUTE2VTx?= NHvuPZBKSzVyPUKuPFYhyrFiMD61OEBvVSCob4KgSHI1KGW6cILld5Nqd25? M2D3flI1QDZ4NUi1
MDA-MB-468 MUjLbY5ie2ViQYPzZZk> NG\iOok4OiCq M2nHVmROW09? MUjJR|UxRTBwMUGgxtEhOC5yMTDuUUBnd3JiRGK0JIV5eHKnc4Ppc44> M3nqRVI1QDZ4NUi1
SUM-159 NFSxO3VMcW6jc3WgRZN{[Xl? MVi3NkBp M1n4N2ROW09? MYXJR|UxRTFwN{KgxtEhOC5|MzDuUUBnd3JiRGK0JIV5eHKnc4Ppc44> MnjYNlQ5PjZ3OEW=
MT-3 MmO0T4lv[XOnIFHzd4F6 M1XWOlczKGh? M3HWXGROW09? M2HjNGlEPTB;NUSuNVEhyrFiND6zNkBvVSCob4KgSHI2KGW6cILld5Nqd25? NWTYfo5COjR6Nk[1PFU>
MDA-MB-468 NELlfHhMcW6jc3WgRZN{[Xl? M4fNfVczKGh? M13TVGROW09? MUHJR|UxRTBwMEegxtEhOC5yMjDuUUBnd3JiRGK1JIV5eHKnc4Ppc44> M4PNdFI1QDZ4NUi1
SUM-159 M1jPNWtqdmG|ZTDBd5NigQ>? MmTIO|IhcA>? MYPEUXNQ M4jSXGlEPTB;NkmuOEDDuSB2LkKzJI5OKG[xcjDEVlUh\XiycnXzd4lwdg>? MmDNNlQ5PjZ3OEW=
MT-3 + NAC Mo\pT4lv[XOnIFHzd4F6 Mn31O|IhcA>? M{PhVmROW09? MoD1TWM2OD13Nj6yJOKyKDJwMEegcm0h\m:{IFTSOUBmgHC{ZYPzbY9v MWWyOFg3PjV6NR?=
MT-3 + SB203580 M2fVSGtqdmG|ZTDBd5NigQ>? NGTtSoo4OiCq MoPrSG1UVw>? MljtTWM2OD1|OD60NUDDuSB3LkCyJI5OKG[xcjDEVlUh\XiycnXzd4lwdg>? Mn;FNlQ5PjZ3OEW=
DB NELSOmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHKNmQyOCCwTR?= M1LYOlI1KGh? M{TMS2ROW09? NVH0bJRzcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9v MmfSNlQ1QDZ3OUW=
SU-DHL-8 M{ezOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzm[YJ5OTBibl2= NH2wTmozPCCq M2rw[GROW09? Mk\sbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;u M3jGfVI1PDh4NUm1
WSU-DLCL2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moj5NVAhdk1? M{PzcVI1KGh? MorJSG1UVw>? NIrZTZpqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44> MV:yOFQ5PjV7NR?=
ACC-2 Ml3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;ic|AuOTByIH7N MkO3NlQhcA>? NVf4N2pQcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M3PLRVI1OzdyOUm1
ACC-2 MWPBdI9xfG:|aYOgRZN{[Xl? NFLoe3IxNTJyIH7N MYeyOEBp MYrpcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NXHyVIQyOjR|N{C5PVU>
ACC-2 MnvVSpVv[3Srb36gRZN{[Xl? MW[wMVIxKG6P MmXpNlQhcA>? MV;pcoNz\WG|ZYOgeIhmKGOxbo\ldpNqd25ib3[gUGM{USC2bzDMR|NKUQ>? NHrPR3EzPDN5MEm5OS=>
BFTC905 NVXwU4pHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXOOWNFOC1zMECwJI5O NWS4dG5oPDhiaNMg NIq1bVJFVVOR MkLqTWM2OD1{MDDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NWOzcmhiOjR{OUe2OFQ>
T24 MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVKwMVExODBibl2= M4W1S|Q5KGkEoB?= M373[mROW09? M3vIU2lEPTB;MkCgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NWfDSmZGOjR{OUe2OFQ>
TSGH8301  MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;Id|kxNTFyMECgcm0> MWC0PEBpyqB? MWDEUXNQ M1TDRmlEPTB;MkCgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NIX0bYYzPDJ7N{[0OC=>
BFTC909 Mo\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYOwMVExODBibl2= MkjxOFghcMLi NX;1e4JPTE2VTx?= MVzJR|UxRTJyIH7NMEBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M3P3UVI1Ojl5NkS0
BFTC905 M1fUb2Fxd3C2b4Ppd{BCe3OjeR?= M3vKR|IxKG6P M2DLdFQ5KGh? MnTZSG1UVw>? MVrpcoR2[2W|IHHwc5B1d3Orcx?= MlHrNlQzQTd4NES=
BFTC905 NFHvVo1HfW6ldHnvckBCe3OjeR?= MmX1NlAhdk1? NUnaPHlNPDhiaB?= NFjMSVZFVVOR MUDk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gUGM{Si2LSR?= MoK3NlQzQTd4NES=
A2780p MnrOSpVv[3Srb36gRZN{[Xl? MXewMVExOCCwTR?= NXrOPJNiOjRiaB?= MnnqSG1UVw>? MmnibY5lfWOnczDTeZJ3cX[rbjDkc5dvemWpdXzheIlwdsLi NFfJOYszPDJ4Mki3OS=>
A2780cis NFXue3RHfW6ldHnvckBCe3OjeR?= NELJSoUxNTFyMDDuUS=> NIS3V5AzPCCq MnTtSG1UVw>? NYr3SGFHcW6mdXPld{BUfXK4aY\pckBld3ewcnXneYxifGmxbtMg MV6yOFI3Ojh5NR?=
A2780p MV;BdI9xfG:|aYOgRZN{[Xl? MXi1MVExOCCwTR?= Mki0NlQwPDhiaB?= NWeyU|hYTE2VTx?= Mnv3bY5kemWjc3XzJIFxd3C2b4Ppd{BqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> MkDjNlQzPjJ6N{W=
A2780cis M4nFbmFxd3C2b4Ppd{BCe3OjeR?= MY[1MVExOCCwTR?= NVu1WVNSOjRxNEigbC=> MlXtSG1UVw>? NUX3c5VscW6lcnXhd4V{KGGyb4D0c5NqeyCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? MlPQNlQzPjJ6N{W=
SH-SY5Y MoLERZBweHSxc3nzJGF{e2G7 M1ntZ|EwOTBxMUCwJOK2VQ>? M1HnS|czKGh? MoHESG1UVw>? NIXXSoVqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NYXadFBmOjR{NUS1OlA>
HL-60 NFrDNFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TOUFczyqCq M3\3fmROW09? NETaSVRKSzVyPUCuN{BvVQ>? M4PIe|I{PjF6OE[y
U937  M4PFTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XSdVczyqCq M{LXeGROW09? MYTJR|UxRTBwODDuUS=> MmDFNlM3OTh6NkK=
HL-60  NU[3W251TnWwY4Tpc44hSXO|YYm= M170eVHDqM7:TR?= NHPvbHg3NzF{L{K0JIg> MYDEUXNQ NHi5WHpqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kB{fXK4aY\pci=> MXGyN|YyQDh4Mh?=
U937  MnnvSpVv[3Srb36gRZN{[Xl? MkHKNeKh|ryP M2HqT|YwOTJxMkSgbC=> MWDEUXNQ M1u2R4lvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJJN2en[rdnnu M1zHNFI{PjF6OE[y
HL-60 MV3BdI9xfG:|aYOgRZN{[Xl? NFu3NpMxNjFxMTFOwG0> MnnMPEBp Ml7ZSG1UVw>? MXrpcoR2[2W|IHHwc5B1d3Orcx?= NYPBUZVUOjN4MUi4OlI>
Sk-NEP-1  MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;yNU0yODByMDDuUS=> NXi2fY9vOjRiaB?= M4rGVWROW09? NHvpNIpKSzVyPUGwNEBvVQ>? NVfPeolLOjN{Nke2PVk>
SK-NEP-1  NGLlRopCeG:ydH;zbZMhSXO|YYm= MnnoOVAwOTByIH7N NVjKSFAzOTJxMkSgbC=> Mo\qSG1UVw>? NES5Z4JqdmS3Y3XzJIFxd3C2b4Ppdy=> MWOyN|I3PzZ7OR?=
TC-32 MmPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TnXFAvOS1zMECwJI5O M4jKdWVEPTB;Mz6wJI5ONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M2HPcVIzQTZzN{[z
TC-71 NGXZUXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTtclFuOC5zLUGwNFAhdk1? NUnNe4tJTUN3ME21Mlchdk1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MlSzNlI6PjF5NkO=
SK-ES-1 NIn6bWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW[wMlEuOTByMDDuUS=> MYnFR|UxRTJwODDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MYCyNlk3OTd4Mx?=
RD-ES NFzZVHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWiwMlEuOTByMDDuUS=> MmD4SWM2OD14LkKgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MoPKNlI6PjF5NkO=
HEK293 M4TQOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfqemYxNjFvMUCwNEBvVQ>? NXfBN2tVTUN3ME2yN{4xKG6PLDDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NUf4fWpCOjJ7NkG3OlM>
M059J M{XvU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MomxNE02OCCwTR?= MVO0PEBp MojObY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M3fL[|IzPzdyMUGw
M059K NXjHfWZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLobVcxNTVyIH7N M{e1PVQ5KGh? M2LkSIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NIDSTFkzOjd5MEGxNC=>
M059J MYDBdI9xfG:|aYOgRZN{[Xl? MkS0N|Ahdk1? NV3uSGRtOjRiaB?= NFnxRo1qdmS3Y3XzJIFxd3C2b4Ppdy=> M4i1N|IzPzdyMUGw
M059K MWfBdI9xfG:|aYOgRZN{[Xl? MVizNEBvVQ>? M1nsXFI1KGh? NXLDfJB6cW6mdXPld{BieG:ydH;zbZM> M3Ltd|IzPzdyMUGw
PANC-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX2wMlAyNTFyMECgcm0> MXe0PEBp MV7JR|UxRTNwNkmgcm0> MmPqNlI4OjN6N{G=
MIAPaCa-2 NIHmfFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;wNE4xOS1zMECwJI5O NH36TXU1QCCq NWD1bXdSUUN3ME2yPU4{PiCwTR?= NIPT[GozOjd{M{i3NS=>
BxPC-3 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXn0eJp3OC5yMT2xNFAxKG6P NX2zc4NmPDhiaB?= MXzJR|UxRTNyLkK2JI5O MnnqNlI4OjN6N{G=
PANC-1 NWG4W3R[TnWwY4Tpc44hSXO|YYm= Ml3LNE0yODByIH7N MYOyOEBp NVy2V2xXcW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBZUUGSIHHu[EB{fXK4aY\pckBmgHC{ZYPzbY9v MYiyNlczOzh5MR?=
MIAPaCa-2 NYDzNWI1TnWwY4Tpc44hSXO|YYm= MoXDNE0yODByIH7N M{jkNFI1KGh? NYDWR2drcW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBZUUGSIHHu[EB{fXK4aY\pckBmgHC{ZYPzbY9v Mn7UNlI4OjN6N{G=
BxPC-3 MmnVSpVv[3Srb36gRZN{[Xl? NX\LZ3F6OC1zMECwJI5O MYCyOEBp MlS5bY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDYTWFRKGGwZDDzeZJ3cX[rbjDlfJBz\XO|aX;u NHzHd5gzOjd{M{i3NS=>
RPMI-7951 MmfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHQS2k2OD1|LkKgcm0> NXjIPZkyOjF5M{e1NFI>
SK-MEL-5 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPHTVUxRTRwMjDuUS=> MU[yNVc{PzVyMh?=
A375 M{jQdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fVT2dKPTB;Nj6zJI5O M3TlNVIyPzN5NUCy
SK-MEL-28 MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfHTVUxRTdwNjDuUS=> MnzvNlE4Ozd3MEK=
SK-MEL-2 MkjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzHTVUxRTFzIH7N MWWyNVc{PzVyMh?=
DB MnzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLNdm41QMLiaB?= MojZS2k2OD1|LkWgcm0> NUi4WJg{OjF{M{e1NFg>
Pfeiffer M3znV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIC3foo1QMLiaB?= MkDrS2k2OD1|Lkmgcm0> MlHZNlEzOzd3MEi=
SU-DHL-5 NHyzNHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGOwb2c1QMLiaB?= MoPKS2k2OD1yLkKzJI5O NVfSfmFUOjF{M{e1NFg>
SU-DHL-8 M2\zdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2G2PVQ5yqCq M2PJWWdKPTB;MT60JI5O MXGyNVI{PzVyOB?=
WSU-DLCL-2 NVXzeWZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPz[oo1QMLiaB?= MkmyS2k2OD1zLkSgcm0> NEXCb44zOTJ|N{WwPC=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Survivin / XIAP / Caspase-7 / Caspase-9 / Caspase-3 / Cleaved Caspase-8 / PARP; 

PubMed: 26771139     


YM155 treatment decreased survivin expression without affecting XIAP and induced cleavage of caspases. Protein expression (caspase-3, -7, -9, -8, PARP) was detected by Western Blot analysis. 

β-catenin / c-Myc / Cyclin D1 / CD44 ; 

PubMed: 26771139     


YM155 inhibited expression of CSC molecules. SGC-7901 cells were treated with YM155 at indicated doses for 24 hours. The protein levels of genes were determined by Western Blot.

p-STAT3 / STAT3 ; 

PubMed: 22723871     


Levels of phosphorylated STAT3 and expression of survivin were analyzed by Western blotting after a 24-hours treatment with YM155 and 48 hours after transfection of 40 nM siRNA.

26771139 22723871
Immunofluorescence
EGFR; 

PubMed: 22723871     


YM155 (10 nM) induced the nuclear EGFR accumulation. PANC-1 cells were stained with anti-EGFR, anti-Alexa Fluor 488, and DAPI after the YM155 treatment. Scale bars: 10 µm.

PARP-1 / PAR ; 

PubMed: 26090615     


A. Nuclear accumulation of active PARP-1 in KYSE410 cells after 12 h of YM155 treatment was evaluated using immunofluorescent analysis. Nuclei were stained with DAPI, as shown in blue. Scale bars: 10 μm. C. Accumulation of the poly-ADP polymer in KYSE410 was evaluated using immunofluorescent analysis after YM155 treatment for 12 h. Nuclei were stained with DAPI, as shown in blue. Scale bars: 10 μm. 

22723871 26090615
Growth inhibition assay
Cell viability; 

PubMed: 29636860     


Cells were grown in 96-well plates for 24 h and treated with the indicated concentrations of YM155 or docetaxel for 72 h, and cell survival was determined by MTT assay.

29636860
体内研究 YM155按3和10 mg/kg皮下注射前列腺移植瘤,结果显示YM155完全抑制PC-3的肿瘤生长,但是重量没有降低,血细胞数也没有下降。药物动力学分析显示YM155作用于肿瘤组织效果很明显。而且,YM155按5 mg/kg作用于PC-3常位移植瘤时肿瘤抑制率达80% 。[1]YM155和γ-射线联用作用于携带H460或Calu6 移植瘤的裸鼠,显示出强抗癌活性。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

- 合并

启动子-荧光酶素报告实验:

使用Pyrobest聚合酶和引物5’-GCGCGCTCGAGTCTAGACATGCGGATATATTC-3’和5’-GCGCGAA-GCTTTGGCGGTTAATGGCGCGC-3’, 从人类基因组DNA中分离2767个碱基对序列的人类survivin基因启动子。在pGL3-Basic质粒的XhoI/HindIII切除位点,内切酶XhoI/HindIII切除产生的PCR片段。产生的质粒称为pSUR-luc。通过DNA测序仪在所有增强序列处测定DNA序列。通过荧光酶素实验,使用短暂转染的HeLa-S3细胞,测定pSUR-luc的活力。使用的pGL3质粒含有SV40启动子和增强子序列。 pSUR-luc和pSV2bsr 质粒通过Lipofectamin2000稳定转染到HeLa细胞中。加入10 μg/mL灭瘟素,根据适当的荧光酶素信号和基因稳定性,筛选HeLa-SURP-luc单一群落。pGL3和pSV2bsr质粒稳定转染到CHO细胞中。加入10 μg/mL灭瘟素,根据适当的荧光酶素信号和基因稳定性,筛选CHO-SV40-luc单一群落。从HeLa-SURP-luc和CHO-SV40-luc群落中获得细胞用于化学筛选。细胞按每孔5×103接种在96孔板上,加入YM155(溶于DMSO中)。24小时后测定荧光酶素活性。通过回归分析计算IC50值。
细胞实验:

[1]

- 合并
  • Cell lines: PC-3, PPC-1, DU145, TSU-Pr1, 22Rv1, SK-MEL-5,和A375细胞
  • Concentrations: ~ 100 nM
  • Incubation Time: 48小时
  • Method:

    PC-3, PPC-1, DU145, TSU-Pr1, 22Rv1, SK-MEL-5,及A375细胞系按5到40×103密度接种在96孔板上。YM155溶解在DMSO中,持续处理细胞48小时。通过sulforhodamine B试剂测定细胞数。


    (Only for Reference)
动物实验:

[1]

- 合并
  • Animal Models: 皮下注射PC-3移植瘤的雄性裸鼠(BALB/c nu/nu)
  • Dosages: 5 mg/kg
  • Administration: 皮下注射,每周持续处理3天,处理3周。
    (Only for Reference)

溶解度 (25°C)

体外 Water 89 mg/mL (200.77 mM)
DMSO 55 mg/mL (124.07 mM)
Ethanol '6 mg/mL
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
Saline
30 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 443.29
化学式

C20H19BrN4O3

CAS号 781661-94-7
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

Survivin Signaling Pathway Map

相关Survivin产品

Tags: 购买YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide)供应商 | 采购YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide)价格 | YM155 (Sepantronium Bromide)生产 | 订购YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID